No Yes Ok

Archive

« Older Entries Newer Entries »

Zealand Pharma has initiated the Phase 3 trial with dasiglucagon for treatment of severe hypoglycemia in children Thursday, September 27th, 2018
The pediatric Phase 3 trial will enroll up to 40 children with Type 1 diabetes and evaluate time to recovery from insulin-induced low blood glucose In the pivotal Phase 3 trial, 99% of the adult Type 1 diabe [...]
argenx reports positive topline results from Phase 2 proof-of-concept trial of efgartigimod in primary immune thrombocytopenia Monday, September 17th, 2018
Favorable safety and tolerability consistent with efgartigimod clinical trials to date   Clinically meaningful platelet count improvements showed clear separation from placebo at increasing response thresh [...]
LSP leads $45 million Series D Financing in Endotronix Monday, September 17th, 2018
Amsterdam, the Netherlands, September 17, 2018 – LSP, Europe’s leading life sciences investor, today announced its investment in Endotronix, Inc., a digital health, medtech company dedicated to advancing the treat [...]
argenx doses first patient in global Phase 3 registration trial of efgartigimod for the treatment of generalized myasthenia gravis Thursday, September 6th, 2018
Breda, the Netherlands / Ghent, Belgium, September 6, 2018 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the trea [...]
Affimed Announces Collaboration with Genentech to Develop Novel NK Cell Engager-based Immunotherapeutics for Multiple Cancer Targets Monday, August 27th, 2018
Affimed will receive $96 million upfront and committed funding and is eligible for up to an additional $5.0 billion including milestone payments, and royalties on sales   Heidelberg, Germany, August 27, 2018 [...]
argenx announces that AbbVie has exercised its exclusive option to license ARGX-115, a novel immuno-oncology antibody Wednesday, August 22nd, 2018
Breda, the Netherlands/Ghent, Belgium, August 22, 2018 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment [...]
Merus Announces Formation of a Scientific Advisory Board Wednesday, August 22nd, 2018
- Key Oncology and Drug Development Professionals to Support Advancement of Merus’ Pipeline of Bispecific Antibodies -    UTRECHT, The Netherlands, Aug. 22, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), [...]
LSP co-leads $85 million (£65 million) Series B Financing in Artios Pharma Friday, August 10th, 2018
LSP returns to support the former KuDOS team that successfully developed the first PARP inhibitor Olaparib   Amsterdam, The Netherlands, August 10, 2018 – LSP, Europe’s leading life sciences investor, tod [...]
argenx receives second preclinical milestone payment under its development agreement with AbbVie Thursday, June 28th, 2018
Breda, the Netherlands/Ghent, Belgium, June 28, 2018 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment [...]
argenx reports interim data from first cohort of Phase 2 proof-of-concept clinical trial of efgartigimod for the treatment of pemphigus vulgaris Wednesday, June 20th, 2018
Rapid disease control observed in 4/6 patients Strong PD effect correlates with improvement in PDAI score  Favorable tolerability profile; Independent Data Monitoring Committee (IDMC) recommends advan [...]

« Older Entries Newer Entries »

2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
Follow us

No Yes Ok

Archive

« Older Entries Newer Entries »

Zealand Pharma has initiated the Phase 3 trial with dasiglucagon for treatment of severe hypoglycemia in children Thursday, September 27th, 2018
The pediatric Phase 3 trial will enroll up to 40 children with Type 1 diabetes and evaluate time to recovery from insulin-induced low blood glucose In the pivotal Phase 3 trial, 99% of the adult Type 1 diabe [...]
argenx reports positive topline results from Phase 2 proof-of-concept trial of efgartigimod in primary immune thrombocytopenia Monday, September 17th, 2018
Favorable safety and tolerability consistent with efgartigimod clinical trials to date   Clinically meaningful platelet count improvements showed clear separation from placebo at increasing response thresh [...]
LSP leads $45 million Series D Financing in Endotronix Monday, September 17th, 2018
Amsterdam, the Netherlands, September 17, 2018 – LSP, Europe’s leading life sciences investor, today announced its investment in Endotronix, Inc., a digital health, medtech company dedicated to advancing the treat [...]
argenx doses first patient in global Phase 3 registration trial of efgartigimod for the treatment of generalized myasthenia gravis Thursday, September 6th, 2018
Breda, the Netherlands / Ghent, Belgium, September 6, 2018 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the trea [...]
Affimed Announces Collaboration with Genentech to Develop Novel NK Cell Engager-based Immunotherapeutics for Multiple Cancer Targets Monday, August 27th, 2018
Affimed will receive $96 million upfront and committed funding and is eligible for up to an additional $5.0 billion including milestone payments, and royalties on sales   Heidelberg, Germany, August 27, 2018 [...]
argenx announces that AbbVie has exercised its exclusive option to license ARGX-115, a novel immuno-oncology antibody Wednesday, August 22nd, 2018
Breda, the Netherlands/Ghent, Belgium, August 22, 2018 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment [...]
Merus Announces Formation of a Scientific Advisory Board Wednesday, August 22nd, 2018
- Key Oncology and Drug Development Professionals to Support Advancement of Merus’ Pipeline of Bispecific Antibodies -    UTRECHT, The Netherlands, Aug. 22, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), [...]
LSP co-leads $85 million (£65 million) Series B Financing in Artios Pharma Friday, August 10th, 2018
LSP returns to support the former KuDOS team that successfully developed the first PARP inhibitor Olaparib   Amsterdam, The Netherlands, August 10, 2018 – LSP, Europe’s leading life sciences investor, tod [...]
argenx receives second preclinical milestone payment under its development agreement with AbbVie Thursday, June 28th, 2018
Breda, the Netherlands/Ghent, Belgium, June 28, 2018 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment [...]
argenx reports interim data from first cohort of Phase 2 proof-of-concept clinical trial of efgartigimod for the treatment of pemphigus vulgaris Wednesday, June 20th, 2018
Rapid disease control observed in 4/6 patients Strong PD effect correlates with improvement in PDAI score  Favorable tolerability profile; Independent Data Monitoring Committee (IDMC) recommends advan [...]

« Older Entries Newer Entries »

2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
X

MONTHLY REPORTS

Here you can subscribe for the monthly report of the LSP Life Sciences Fund